Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: 3 - What They Never Told You

MRNA Stock Gets a Shot in the Arm as FDA Approves Moderna Flu Vaccine

Moderna has secured FDA approval for its flu vaccine mFLUSIVA. But does that warrant buying MRNA shares today? Let’s find out!

Barchart

FDA approves first mRNA vaccine for seasonal flu

The Food and Drug Administration's approval of an mRNA vaccine for flu comes after the agency initially refused to review the approval request for the shot.

LiveScience

First mRNA-based flu shot approved in US - despite RFK Jr’s objections to the science

Health Secretary Robert F. Kennedy Jr pulled $500 million in funding for mRNA vaccine development last year - the medical community said the U.S. would pay the price in dollars and lives

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

New kind of flu shot is on the way as the FDA approves Moderna's mRNA-based vaccine

The Food and Drug Administration has approved a new flu vaccine for older people, the first made with the same mRNA technology that was key to ending the COVID-19 pandemic

The Independent UK

Moderna starts human trials for Bundibugyo Ebola vaccine as Congo's outbreak continues

Moderna has vaccinated the first participants in a trial for a Bundibugyo Ebola vaccine, as the Democratic Republic of Congo continues to battle its fastest-growing outbreak on record.

Euronews

Moderna Says Its Norovirus Vaccine Missed an Early Success Threshold, and the Trial Will Continue

Moderna's norovirus vaccine did not meet interim success criteria in phase 3. The trial continues blinded with a new cohort. Here is what that means.

Medical Daily

Are Wall Street Analysts Predicting Moderna Stock Will Climb or Sink?

Despite Moderna's stellar outperformance over the past year, Wall Street analysts remain cautious about the stock's longer-term prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

The First Vaccine Built for This Ebola Strain Has Entered Human Testing as the DRC Outbreak Becomes the Country's Largest

Oxford launched the first Phase 1 trial of a Bundibugyo Ebola vaccine. Licensed Ebola vaccines target a different species and do not cover this strain.

Medical Daily

Earnings Preview: What To Expect From Moderna’s Report

Moderna is likely to announce its fiscal second-quarter earnings by the end of this month, and analysts expect its losses to narrow.

Barchart

Short Squeeze Alert—Moderna Stock Surges on New Strategy

Moderna shares rose nearly 20% after Science Day, driven partly by a short squeeze, while its mRNA pipeline beyond vaccines faces a multi-year path to revenue.

MarketBeat

MRNA Stock Spikes as Moderna Shares mRNA Pipeline Update

Moderna stock soars on positive updates during the Science Day presentation. Jefferies sees significant further upside in MRNA shares.

Barchart

Stocks Struggle After OpenAI IPO Blow: Stock Market Today

Stocks took an early hit on news that ChatGPT parent OpenAI might push its public offering to 2027, and a midday recovery faded into the close.

Kiplinger

US stocks: US market ends lower as tech stocks weigh on sentiment

Wall Street ended lower on Friday, with AI chip stocks experiencing a significant downturn while Moderna and other healthcare companies surged. Investors are weighing the long-term potential of AI against concerns about the substantial investment required for data centers. Inflationary pressures, fueled by energy prices and chip costs, remain a…

The Economic Times

FDA Panel Backs Moderna's First mRNA Flu Shot — What It Could Mean for Your Fall Vaccine

FDA advisers unanimously backed Moderna's mRNA flu vaccine mFlusiva on June 18. Here's what the 9-0 vote means for fall 2026 vaccination and who it would cover.

Medical Daily

Get all your
news in one place.

100's of premium titles.
One news app.

AAP

FDA panel backs first-of-its-kind flu vaccine using mRNA technology

A new kind of flu vaccine is moving a step closer to the U.S. market

Medical Daily

FDA Advisory Panel Votes Today on First mRNA Flu Vaccine as MFLUSIVA Phase 3 Results Face Intense Scrutiny

FDA VRBPAC votes June 18 on Moderna's MFLUSIVA — the first mRNA flu vaccine. Phase 3 showed 26.6% RVE vs. standard dose; 47.9% vs. healthcare outcomes. PDUFA August 5, 2026.

AAP

FDA panel considers a first-of-its-kind flu vaccine using mRNA technology

U.S. health advisers are debating a new kind of flu vaccine

The Independent UK

New mRNA flu vaccine faces scrutiny ahead of key FDA decision

U.S. health advisers are debating a new kind of flu vaccine

Get all your
news in one place.

100's of premium titles.
One news app.

Euronews

‘I worry deeply about bioterrorism’: Is Europe sufficiently prepared for another pandemic?

Internationally renowned for their life-saving Covid vaccine, what is Moderna doing now? Their CEO joins us in the studio to discuss bioterrorism, pandemic preparedness and cancer treatment.

LiveScience

3 new Ebola vaccines are being fast-tracked amid the current outbreak — when could they be ready?

The Bundibugyo virus driving the current Ebola outbreak has no approved vaccine, but researchers are leveraging decades of vaccine innovation in an effort to change that.

The Independent UK

Oxford University and Moderna to trial pioneering cancer vaccine

IN FULL

The Independent UK

Oxford University and Moderna launch trials of vaccine that could prevent cancer

The jab targets patients with Lynch syndrome, who are at high risk of colorectal and ovarian cancer

Barchart

Moderna Stock: Is MRNA Outperforming the Health Care Sector?

Although Moderna has outperformed the broader health care sector over the last 12 months, analysts maintain a cautious stance on the stock’s future outlook.

The Economic Times

Serum Institute of India to manufacture Oxford Ebola vaccine backed by $8.6 million CEPI funding

Serum Institute of India will produce clinical trial doses of a new Ebola vaccine from Oxford University. This initiative is backed by fresh funding to combat a spreading outbreak in Africa. The vaccine uses technology similar to the Oxford-AstraZeneca Covid-19 vaccine. This partnership aims to accelerate development and ensure access…

The Economic Times

Moderna and other groups get $60 million to develop Ebola vaccine

CEPI is investing around $60 million to speed up the creation of vaccines against the deadly Ebola Bundibugyo virus. This funding will support Moderna, the University of Oxford, and the International AIDS Vaccine Initiative. The goal is to have trial-ready vaccines within months.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

the Democratic Republic of Congo

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.